Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved a new chimeric antigen receptor (CAR) T-cell therapy, a study identified foods that reduce lung cancer risk, and more.
Diets high in fiber and yogurt are associated with a reduced risk of lung cancer, according to a study published in JAMA Oncology. “Our findings suggest a potential protective role of prebiotics and probiotics against lung carcinogenesis,” the researchers wrote.
Women with diabetes have suboptimal breast, cervical, and colorectal cancer screening rates compared with women without diabetes, according to a study published in Diabetologia.
Revlimid® (lenalidomide) significantly delayed disease progression in patients with smoldering multiple myeloma, according to a study published in the Journal of Clinical Oncology.
Anxiety and depression in patients with cancer are associated with increased pain intensity, according to a study presented at the Supportive Care in Oncology Symposium.
The FDA granted Regenerative Medicine Advanced Therapy designation to the investigational CAR T-cell therapy CT053, a fully human anti-B-cell maturation antigen autologous CAR T-cell therapy, for the treatment of relapsed/refractory multiple myeloma.
In case you missed it, more hem/onc headlines are featured below:
- Imfinzi Combination Treatment Successful in Late-stage Lung Cancer
- Combo Ibrutinib plus Venetoclax Treatment Effective in Relapsed CLL
- Early Signs of Heart Disease May Indicate Cancer Risk as Well
- Interleukin Inhibitors Increase Infection, Cancer Risk for Patients With Rheumatologic Diseases
- Childhood Cancer Survivors At Risk for Breast Cancer